Determine the necessary mass, volume, or concentration for preparing a solution.
Mavodelpar - ≥99% , CAS No.1604815-32-8
AVAILABLE TO ORDER
GRADE & PURITY ≥99%
Storage
Store at 2-8°C,Desiccated
Shipped In
Wet ice
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at 2-8°C,Desiccated Ships Wet ice Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
In Vivo
Mavodelpar (10 mg/kg; i.p., once daily, from 6 to 17 weeks of age) effectively suppresses glomerular injury and renal fibrosis, and decreases levels of fibrosis-related proteins . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male and female B6129SF1-Col4a3 -/- mice Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age Result: Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.
Form:Solid
Specifications
Specifications & Purity
≥99%
Biochemical and Physiological Mechanisms
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
Storage
Store at 2-8°C, Desiccated
Shipped In
Wet ice
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
AGONIST
Purity
≥99%
Names and Identifiers
| Isomeric SMILES | CC1=C(C=CC(=C1)OC/C=C(\C2=CC=C(C=C2)C#CCN3CCOCC3)/C4=CC=C(C=C4)F)OCC(=O)[O-].[Na+] |
|---|---|
| PubChem CID | 122662515 |
| Molecular Weight | 537.55 |
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
| Solubility | DMSO : 120 mg/mL (223.24 mM; Need ultrasonic) |
|---|
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.